-
November 20, 2012 Lupin launches Generic TRICOR® Tablets
-
October 30, 2012 Consistent Growth, Robust Profits Quarter II Results, FY 2013-14 Net Sales up 18%; EBITDA up 42%; Net profit up 40%
-
October 25, 2012 Lupin launches Generic Seasonale® Tablets; receives FDA approval
-
October 23, 2012 Record Sales & Profits Quarter II Results, FY 2012-13 Net Sales up 29%, EBITDA up 28%, PBT up 27%, PAT up 9%
-
October 22, 2012 Lupin Receives FDA Approval for its New Drug Application for Antara® Capsules
-
October 18, 2012 Lupin receives FDA approval for its Oral Contraceptive Kurvelo® Tablets; The Generic of Nordette® Tablets
-
October 17, 2012 Lupin receives FDA approval for Generic Avapro® Tablets
-
September 27, 2012 Lupin receives FDA approval for its Oral Contraceptive VyfemlaTM Tablets Generic of Ovcon® 35 Tablets
-
September 13, 2012 Lupin receives FDA approval for Generic Lexapro® Tablets e® Tablets
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications